Determining an Adaptive Exclusion Procedure following Discovery of an Association between the Whole Genome and Adverse Drug Reactions

  • Ting-Li SuEmail author
  • Helene Thygesen
  • John Whitehead
  • Clive Bowman


This article concerns the identification of associations between the incidence of adverse drug reactions and features apparent from whole genome scans of patients together with the subsequent implementation of an adaptive exclusion procedure within a drug development program. Our context is not a retrospective assessment of a large and complete database: instead we are concerned with identifying such a relationship during a drug development program and the consequences for the future conduct of that program. In particular, we seek methods for identifying changes to the exclusion criteria that will prevent future patients at high risk of an adverse reaction from continuing to be recruited. We discuss the levels of evidence needed to amend an existing recruitment policy, how this can be done, and how to evaluate and revise the reformulated recruitment policy as the trials continue. The approach will be illustrated using clinical trial data to demonstrate its potential for making an immediate reduction in the incidence of adverse drug reactions.

Key Words

Adverse drug reactions; Clinical trial Drug development Genotyping Pharmacogenomics Pharmacovigilance SNP 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mallal S, Phillips E, Carosi G, et al.; PREDICT-1 Study Team. HLA-B* 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568–579.CrossRefGoogle Scholar
  2. 2.
    Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D; CNA106030 Study Team. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008;7: 121–129.CrossRefGoogle Scholar
  3. 3.
    Kelly P. Stallard N, Zhou Y, Whitehead J, Bowman C. Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs. Stat Med. 2006;25: 3081–3092.CrossRefGoogle Scholar
  4. 4.
    Whitehead J, Kelly P, Zhou Y, Stallard N, Thygesen H, Bowman C. Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme. Pharm Stat. 2009;8: 287–300.CrossRefGoogle Scholar
  5. 5.
    Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Sac B. 1996;58:267–288.Google Scholar
  6. 6.
    Genkin A, Lewis DD, Madigan D. Large-scale Bayesian logistic regression for text categorization. Technometrics. 2007;49:291–304.CrossRefGoogle Scholar
  7. 7.
    Clayton D. SNPHAP: A program for estimating frequencies of large haplotypes of SNPs (Version 1.3). 2002.
  8. 8.
    Souverein OW. Defesche JC, Zwinderman AH, Kastelein JJ.Tanck MW. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hyper-cholesterolaemia. Eur Heart J. 2007;28:299–304.CrossRefGoogle Scholar
  9. 9.
    Roses AD, Pharmacogenetics in drug discovery and development; a translationsl perspective, Nat Rev Drug Discov. 2008;7:807–817.CrossRefGoogle Scholar
  10. 10.
    UK Telegraph. Star Trek gadget checks suitability to medicines. February 16, 2009.

Copyright information

© Drug Information Association, Inc 2010

Authors and Affiliations

  • Ting-Li Su
    • 1
    Email author
  • Helene Thygesen
    • 1
  • John Whitehead
    • 1
  • Clive Bowman
    • 2
  1. 1.Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Fylde CollegeLancaster UniversityLancasterUK
  2. 2.School of Biological SciencesUniversity of ReadingUK

Personalised recommendations